Ivermectin and outcomes from Covid‐19 pneumonia: A systematic review and meta‐analysis of randomized clinical trial studies
Timotius Ivan Hariyanto, Devina Adella Halim, Jane Rosalind, Catherine Gunawan, Andree Kurniawan
Reviews in Medical Virology, doi:10.1002/rmv.2265
Ivermectin is an FDA-approved drug for a parasitic disease that has broad antiviral activity. This study aims to analyse the efficacy of ivermectin in improving the Covid-19 outcomes. We systematically searched the PubMed, Europe PMC and ClinicalTrials.gov database using specific keywords related to our aims until 10th May 2021. All published randomized clinical trial studies on Covid-19 and ivermectin were retrieved. The quality of the study was assessed using Jadad scale assessment tool for clinical trial studies. Statistical analysis was done using Review Manager 5.4 software. A total of 19 studies with 2768 Covid-19 patients were included in this meta-analysis. This meta-analysis showed that ivermectin was associated with reduction in severity of Covid-19 (RR 0.43 [95% CI 0.23-0.81], p = 0.008), reduction of mortality (RR 0.31 [95% CI 0.15-0.62], p = 0.001), higher negative RT-PCR test results rate (RR 1.23 [95% CI 1.01-1.51], p = 0.04), shorter time to negative RT-PCR test results (mean difference [MD] −3.29 [95% CI −5.69, −0.89], p = 0.007), higher symptoms alleviations rate (RR 1.23 [95% CI 1.03−1.46], p = 0.02), shorter time to symptoms alleviations (MD −0.68 [95% CI −1.07, −0.29], p = 0.0007) and shorter time to hospital discharge (MD −2.66 [95% CI −4.49, −0.82], p = 0.004). Our study suggests that ivermectin may offer beneficial effects towards Covid-19 outcomes. More randomized clinical trial studies are still needed to confirm the results of our study.
CONFLICT OF INTEREST The Authors declare that there is no conflict of interest.
AUTHORS CONTRIBUTION
Conceptualization
References
Ahmed, Karim, Ross, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis,
doi:10.1016/j.ijid.2020.11.191Babalola, Bode, Ajayi, Ivermectin shows clinical benefits in mild to moderate COVID19: a randomised controlled double-blind, dose-response study in Lagos, QJM,
doi:10.1093/qjmed/hcab035Banerjee, Nandy, Dalai, Ahmed, The battle against COVID 19 pandemic: what we need to know before we "test fire" ivermectin, Drug Res (Stuttg),
doi:10.1055/a-1185-8913Buonaguro, Ascierto, Morse, Covid-19: time for a paradigm change, Rev Med Virol,
doi:10.1002/rmv.2134Chaccour, Casellas, Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalMedicine,
doi:10.21203/rs.3.rs-116547/v1Chachar, Khan, Asif, Khushbakht, Khaqan et al., Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients, Int J Sci,
doi:10.18483/ijSci.2378Chowdhury, Shahbaz, Karim, Islam, Guo et al., A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients, EJMO,
doi:10.21203/rs.3.rs-38896/v1Elgazzar, Hany, Youssef, Hafez, Moussa et al., Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic,
doi:10.21203/rs.3.rs-100956/v2Elsawah, Elsokary, Abdallah, Elshafie, Efficacy and safety of remdesivir in hospitalized Covid-19 patients: systematic review and meta-analysis including network meta-analysis, Rev Med Virol,
doi:10.1002/rmv.2187Gonzalez, Gamez, Enciso, Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial,
doi:10.1101/2021.02.18.21252037Götz, Magar, Dornfeld, Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci Rep,
doi:10.1038/srep23138Hariyanto, Christian, Kurniawan, Human immunodeficiency virus and mortality from coronavirus disease 2019: a systematic review and meta-analysis, South Afr J HIV Med,
doi:10.4102/sajhivmed.v22i1.1220Hariyanto, Halim, Gunawan, Kurniawan, Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical trial studies, Rev Med Virol
Hariyanto, Halim, Jodhinata, Yanto, Kurniawan, Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis, Clin Exp Pharmacol Physiol,
doi:10.1111/1440-1681.13488Hariyanto, Hardyson, Kurniawan, Efficacy and safety of tocilizumab for coronavirus disease 2019 (Covid-19) patients: a systematic review and meta-analysis, Drug Res (Stuttg),
doi:10.1055/a-1336-2371Hariyanto, Japar, Kwenandar, Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: a systematic review and meta-analysis, Am J Emerg Med,
doi:10.1016/j.ajem.2020.12.076Hariyanto, Kurniawan, Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression, J Diabetes Metab Disord,
doi:10.1007/s40200-021-00777-4Hariyanto, Kurniawan, Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection, Diabetes Metab Syndr,
doi:10.1016/j.dsx.2020.07.044Hariyanto, None
Hariyanto, None
Hariyanto, Prasetya, Kurniawan, Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection, Dig Liver Dis,
doi:10.1016/j.dld.2020.10.001Hariyanto, Putri, Situmeang, Kurniawan, Dementia is associated with severe coronavirus disease 2019 (COVID-19) infection, Am J Med Sci,
doi:10.1016/j.amjms.2020.10.026Hariyanto, Rizki, Kurniawan, Anosmia/Hyposmia is a good predictor of coronavirus disease 2019 (COVID-19) infection: a meta-analysis, Int Arch Otorhinolaryngol,
doi:10.1055/s-0040-1719120Hashim, Maulood, Rasheed, Fatak, Kabah et al., Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq,
doi:10.1101/2020.10.26.20219345Huang, Wang, Chen, Song, Liu et al., Perioperative antibiotics to prevent acute endophthalmitis after ophthalmic surgery: a systematic review and meta-analysis, PLoS One,
doi:10.1371/journal.pone.0166141Jadad, Moore, Carroll, Assessing the quality of reports of randomized clinical trials: is blinding necessary?, Contr Clin Trials,
doi:10.1016/0197-2456(95)00134-4Kishoria, Mathur, Parmar, Ivermectin as adjuvant to hydroxychloroquine in patients resistant to standard treatment for sars-cov-2: results of an open-label randomized clinical study. Paripex, -Indian J Res,
doi:10.36106/paripexLópez-Medina, López, Hurtado, Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, J Am Med Assoc,
doi:10.1001/jama.2021.3071Mahmud, Rahman, Alam, Clinical trial of ivermectin plus doxycycline for the treatment of confirmed covid-19 infection
Mulchandani, Lyngdoh, Kakkar, Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis, Eur J Clin Invest,
doi:10.1111/eci.13429Niaee, Gheibi, Namdar, Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial,
doi:10.21203/rs.3.rs-109670/v1Okumuş, Demirtürk, Çetinkaya, Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients, BMC Infect Dis,
doi:10.1186/s12879-021-06104-9Podder, Chowdhury, Sina, Haque, Outcome of ivermectin treated mild to moderate COVID-19 cases: a singlecentre, open-label, randomized controlled study, IMC J Med Sci
Putri, Hariyanto, Hananto, Christian, Situmeang et al., meta-analysis, and meta-regression
Ravikitri, Pattadar, Raj, Ivermectin as a potential treatment for mild to moderate COVID-19-a double blind randomized placebo-controlled trial, medRxiv,
doi:10.1101/2021.01.05.21249310Rodriguez-Morales, Cardona-Ospina, Ocampo, Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis, Trav Med Infect Dis,
doi:10.1016/j.tmaid.2020.101623Shahbaznejad, Davoudi, Eslami, Effect of ivermectin on COVID-19: a multicenter double-blind randomized controlled clinical trial, Clin Ther,
doi:10.1016/j.clinthera.2021.04.007Shouman, Nafae, Ragab, Use of Ivermectin as a prophylactic option in asymptomatic family close contacts for patients with COVID-19
Tay, Fraser, Chan, Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antivir Res,
doi:10.1016/j.antiviral.2013.06.002Terrin, Schmid, Lau, Olkin, Adjusting for publication bias in the presence of heterogeneity, Stat Med,
doi:10.1002/sim.1461Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J,
doi:10.1042/BJ20120150Wan, Wang, Liu, Tong, Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range, BMC Med Res Methodol,
doi:10.1186/1471-2288-14-135Zhang, Song, Ci, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res,
doi:10.1007/s00011-008-8007-8
